

GRADE Table 2. Safety of pertussis vaccines in immunocompetent infants and children

GRADE Table 2 a. Safety of Whole Cell Pertussis Vaccines (wP) in Immunocompetent Infants and Children

Population : Immunocompetent Infants and children
Intervention : Whole Cell Pertussis Vaccines
Comparison : No vaccine or control
Outcome : Serious adverse events following Immunization

<i>In immunocompetent individuals, what is the incidence of serious adverse events following immunization (versus no vaccine or control) with any dose of wP vaccines?</i>				
		Rating	Adjustment to rating	
Quality Assessment	No. of studies/starting rating		32 RCT	4
	Factors decreasing confidence	Limitation in study design	None serious	0
		Inconsistency	None serious	0
		Indirectness	None serious	0
		Imprecision	None serious	0
		Publication Bias	None serious	0
	Factors increasing confidence	Large effect	Not applicable	0
		Dose-response	Not applicable	0
		Antagonistic bias and confounding	Not applicable	0
	Final numerical rating of quality of evidence			4
Summary of findings	Statement on quality of evidence		Evidence supports a high level of confidence that the true effect lies close to that of the estimate of the effect on the health outcome.	
	Conclusion		Evidence supports a high degree of confidence in the estimate of the effect that incidence of serious adverse events following whole cell pertussis vaccination is low. From the reviewed articles, there is no significant risk of serious adverse events following administration of wP.	

GRADE Table 2 b. Safety of Acellular Pertussis Vaccines (aP) in Immunocompetent Infants and Children

Population : Immunocompetent Infants and children
Intervention : Acellular Pertussis Vaccines
Comparison : No vaccine or control
Outcome : Serious adverse events following immunization

<i>In immunocompetent individuals, what is the incidence of serious adverse events following immunization (versus no vaccine or control) with any dose of aP vaccines?</i>				
		Rating	Adjustment to rating	
Factors	No. of studies/starting rating		33 RCT	4
	Factors	Limitation in study design	None serious	0
		Inconsistency	None serious	0

Quality Assessment	decreasing confidence	Indirectness	None serious	0
		Imprecision	None serious	0
		Publication Bias	None serious	0
	Factors increasing confidence	Large effect	Not applicable	0
		Dose-response	Not applicable	0
		Antagonistic bias and confounding	Not applicable	0
	Final numerical rating of quality of evidence			4
Summary of findings	Statement on quality of evidence		Evidence supports a high level of confidence that the true effect lies close to that of the estimate of the effect on the health outcome.	
	Conclusion		Evidence supports a high degree of confidence in the estimate of the effect that incidence of serious adverse events following acellular pertussis vaccination is low. From the reviewed articles, there is no significant risk of serious adverse events following administration of aP.	

References

1. Afari EA, Kamiya Y, Nkrumah FK, Dunyo SK, Akpedonu P, Kamiya H, et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. *Annals of Tropical Paediatrics* 1996;16(1):39-48. [MEDLINE: 1996260449]
2. Anderson EL, Belshe RB, Bartram J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. *J Infect Dis* 1988;157(4):731-7.
3. Anderson EL, Mink CM, Berlin BS, Shih CN, Tung FF, Belshe RB. Acellular pertussis vaccines in infants: evaluation of single component and two-component products. *Vaccine* 1994;12(1):28-31. ISSN: CN-00098847.
4. Anonymous. Placebo-controlled trial of two acellular pertussis vaccines in Sweden—protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. *Lancet* 1988;1(8592): 955-60.
5. Auerbach BS, Lake AM, Wilson ME, Willingham FF, Shematek J, Moulton L, et al. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine. *Biologicals* 1998;26(2):145-53.
6. Blennow M, Granstrom M, Jaatmaa E, Olin P. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. *Pediatrics* 1988; 82(3):293-9. [MEDLINE: 1988303187]
7. Blennow M, Granstrom M, Olin P, Tiru M, Jaatmaa E, Askelof P, et al. Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6. *Dev Biol Stand* 1986;65:185-90.
8. Blumberg DA, Mink CM, Cherry JD, Johnson C, Garber R, Plotkin SA, et al. Comparison of acellular and wholecell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group. *Journal of Pediatrics* 1991;119(2):194-204. [MEDLINE: 1991318373]
9. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. *Pediatrics* 1995;96(3 Pt 2 Sep):557-66.
10. Edwards KM, Bradley RB, Decker MD, Palmer PS, Van Savage J, Taylor JC, et al. Evaluation of a new highly purified pertussis vaccine in infants and children. *J Infect Dis* 1989;160(5):832-7.

11. Edwards KM, Lawrence E, Wright PF. Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components. *American Journal of Diseases of Children* 1986;140(9):867-71. [MEDLINE: 1986292846]
12. Feldman S, Perry S, Andrew M, Jones L, Moffitt JE. Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children. *J Pediatr* 1992;121(6):857-61.
13. Feldman S, Perry CS, Andrew M, Jones L, Moffitt JE, Lamb D, et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. *Southern Med. J.* 1993; 86(3):269-75, 284.
14. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. *New Engl J Med* 1996;334(6 Feb 8):341-8.
15. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. *New Engl J Med* 1996;334(6 Feb 8):349-55.
16. Halperin SA, Barreto L, Eastwood BJ, Law B, Roberts EA. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. *Archives of Pediatrics and Adolescent Medicine* 1994;148(11):1220-4. [MEDLINE: 1995005321]
17. Halperin SA, Mills E, Barreto L, Pim C, Eastwood BJ. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen month- old children immunized with either whole cell or acellular pertussis vaccine at two. *Pediatr Infect Dis J* 1995;14(9):792-7.
18. Halperin SA, Eastwood BJ, Barreto L, Friesen B, Medd L, Meekison W, et al. Adverse reactions and antibody response to four doses of acellular or whole-cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. *Vaccine* 1996;14(8):767-72. [MEDLINE: 1996414822].
19. Heijbel H, Ciofi degli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F, et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. *Developments in Biological Standardization* 1997;89:101-3. [MEDLINE: 1997418333]
20. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. *Vaccine* 2003;21(17-18):2003-2014.
21. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. *Lancet* 1997;350(9091):1569-77.
22. Pichichero ME, Badgett JT, Rodgers Jr GC, McLinn S, Trevino-Scatterday B, Nelson JD. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18-to 24-month old children. *Pediatr Infect Dis J* 1987;6(4):352-63.
23. Pichichero ME, Francis AB, Blatter MM, Reisinger KS, Green JL, Marsocci SM, et al. Acellular pertussis vaccination of 2-month-old infants in the United States. *Pediatrics* 1992;89(5 Pt 1 May):882-7.
24. Pichichero ME, Francis AB, Marsocci SM, Green JL, Disney FA. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants. *Am J Dis Child* 1993;147(3):295-9.
25. Pichichero ME, Green JL, Francis AB, Marsocci SM, Lynd AM, Litterer T. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children. *Pediatr Infect Dis J* 1994;13(3):193-6.
26. Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. *Pediatrics* 1997;100(5):772-88.
27. Podda A, De Luca EC, Contu B, Furlan R, Maida A, Moiraghi A, et al. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. *J Pediatr* 1994;124(6):921-6.

28. Simondon F, Yam A, Gagnepain JY, Wassilak S, Danve B, Cadoz M. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. *Eur J Clin Microbiol Infect Dis* 1996;15(12):927-32.
29. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteaman I, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. *Vaccine* 1997;15(15):1606-12.
30. Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Überall M, Laussucq S, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. *Pediatrics* 1998;101(1):1-11.
31. Stout MG. U.S. clinical trials with Takeda acellular pertussis vaccine, English. *Tokai J Exp Clin Med* 1988;13(Suppl):21-8.
32. Trollfors B, Taranger J, Lagergard T, Lind L, Sundh V, Zackrisson G, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. *New Engl J Med* 1995;333(16 Oct 19):1045-50.
33. Vanura H, Just M, Ambrosch F, Berger RM, Bogaerts H, Wynen J, et al. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine. *Vaccine* 1994;12(3):210-4.
34. Wiersbitzky S, Bock SL, Bruns R, Clemens R, Graul G, Köditz H, et al. Verträglichkeit und Immunogenität einer 3-Komponentenacellulären Pertussis-Vakzine (DTPa) im Vergleich zur klassischen DTPg-Vakzine. *Monatsschr Kinderheilkd* 1996;144:159-66.
35. Zhang L, Prietsch S, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. *The Cochrane database of systematic reviews* 2014;9:CD001478.